NSE: AUROPHARMA
AUROBINDO PHARMA LTD
Price history
+7.13% over 3M
Performance
52-week range
Position in day range
AUROPHARMA stock DNA
Signals computed live from NSE price history — trend, momentum, volatility and participation in one view.
Trend
Uptrend
50-DMA ₹1,661.87
RSI (14)
52
Neutral momentum
Volatility (ATR)
2.81%
Moderate
Close streak
4d up
Volume vs 20d avg
1.14x
From 52W high
-3.37%
Up from 52W low
+55.48%
Green days (20)
9/20
Monthly seasonality
Average monthly move for AUROPHARMA across the available price history.
Key statistics
Open
1,652
Day high
1,687
Day low
1,647.2
Prev close
1,659.9
Volume
9.53 L
Avg vol (20d)
8.34 L
52W high
1,740
52W low
1,091.2
AUROPHARMA quarterly results
All AUROPHARMA results →Next results date
4 Nov 2026
Last results date
—
Reports published
Coverage coming soon
Revenue
₹9,106 cr
+16.9% YoY
Net profit
₹1,033 cr
+25.2% YoY
Operating profit
₹1,394 cr
+16.4% YoY
EPS
₹17.86
+25.8% YoY
Swipe sideways to see all columns →
| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|---|---|---|---|---|---|---|---|
| Q1 FY272026-06-30 | ₹9,106 cr | ₹1,394 cr | ₹1,033 cr | 15.3% | 11.3% | ₹17.86 | +25.2% | +12.1% |
| Q4 FY262026-03-31 | ₹8,752 cr | ₹1,322 cr | ₹921 cr | 15.1% | 10.5% | ₹15.86 | +2.0% | +1.2% |
| Q3 FY262025-12-31 | ₹8,605 cr | ₹1,309 cr | ₹910 cr | 15.2% | 10.6% | ₹15.67 | — | +10.4% |
| Q1 FY262025-06-30 | ₹7,792 cr | ₹1,198 cr | ₹825 cr | 15.4% | 10.6% | ₹14.20 | — | -8.7% |
| Q4 FY252025-03-31 | ₹8,381 cr | ₹1,347 cr | ₹903 cr | 16.1% | 10.8% | ₹15.56 | — | — |
| TTM (last 4 quarters) | ₹34,254 cr | ₹5,223 cr | ₹3,689 cr | 15.2% | 10.8% | ₹63.59 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
Latest coverage
Aurobindo Pharma Ended Lower to ₹1,672.00 — Should Investors Read This as a Trend or a One-Day Move?
Aurobindo Pharma (AUROPHARMA) last traded at ₹1,672.00, -25.70 (-1.51%). We read the exchange board, the volume against its own average, and what a shareholder should actually do with this information.
AUROPHARMA in Focus: Aurobindo Pharma Share Price Opens Gap-Up at ₹1,688.00 on Rising Newsflow
Aurobindo Pharma (AUROPHARMA) trades at ₹1,660.00, -19.80 (-1.19%). We read the exchange board, the volume against its own average, and what a shareholder should actually do with this information.
AUROPHARMA in Focus: Aurobindo Pharma Share Price Hits 52-Week High, Up 4.18% on Rising Newsflow
Aurobindo Pharma (AUROPHARMA) trades at ₹1,717.00, +71.70 (+4.18%) as the in-focus story plays out. Live board, day range, twelve-month context and the follow-up that decides the next session.
Latest market news
Quarterly Results Lead Market Newsroom Heatmap on 31 October 2026
Quarterly results dominate financial newsrooms with 37 headlines across four major publishers on 31 October 2026, followed closely by industry trends, telecom, and technology shifts.
PB Fintech Limited Q2 FY27 Results: Net Profit ₹192 cr
PB Fintech Limited Q2 FY27 consolidated results: revenue from operations of ₹2,178 cr and net profit of ₹192 cr.
Reliance Industries Limited Q2 FY27 Results: Net Profit ₹29,550 cr
Reliance Industries Limited Q2 FY27 consolidated results: revenue from operations of ₹3,32,861 cr and net profit of ₹29,550 cr.
The Phoenix Mills Limited Q2 FY27 Results: Net Profit ₹127 cr
The Phoenix Mills Limited Q2 FY27 standalone results: revenue from operations of ₹141 cr and net profit of ₹127 cr.
Dixon Technologies (India) Limited Q2 FY27 Results: Net Profit ₹411 cr
Dixon Technologies (India) Limited Q2 FY27 consolidated results: revenue from operations of ₹21,794 cr and net profit of ₹411 cr.
Bank Of Baroda Q2 FY27 Results: Net Profit ₹6,532 cr
Bank Of Baroda Q2 FY27 standalone results: revenue from operations of ₹35,085 cr and net profit of ₹6,532 cr.
Price and history data from NSE via Upstox. For information only, not investment advice.